Glaukos Corp - Asset Resilience Ratio

Latest as of September 2025: 17.56%

Glaukos Corp (GKOS) has an Asset Resilience Ratio of 17.56% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does Glaukos Corp carry for a breakdown of total debt and financial obligations.

Liquid Assets

$175.47 Million
Cash + Short-term Investments

Total Assets

$999.38 Million
All company assets

Resilience Assessment

Good
Financial Resilience Level

Asset Resilience Ratio Trend (2013–2024)

This chart shows how Glaukos Corp's Asset Resilience Ratio has changed over time. See shareholders equity of Glaukos Corp for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Glaukos Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Glaukos Corp.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $175.47 Million 17.56%
Total Liquid Assets $175.47 Million 17.56%

Asset Resilience Insights

  • Good Liquidity Position: Glaukos Corp maintains a healthy 17.56% of assets in liquid form.
  • This level provides good financial flexibility while maintaining productive asset deployment.
  • The company has significant short-term investments, indicating active treasury management.

Glaukos Corp Industry Peers by Asset Resilience Ratio

Compare Glaukos Corp's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Jafron Biomedical Co Ltd
SHE:300529
Medical Devices 36.63%
Sinocare Inc
SHE:300298
Medical Devices 3.53%
Shanghai Kinetic Medical Co
SHE:300326
Medical Devices 28.89%
Eurobio Scientific SA
PA:ALERS
Medical Devices 10.52%
EBR Systems Inc
AU:EBR
Medical Devices 48.75%
Aroa Biosurgery Ltd
AU:ARX
Medical Devices 12.13%
Medprin Regenerative Medical Technologies Co. Ltd.
SHE:301033
Medical Devices 19.31%
Affluent Medical SAS
PA:AFME
Medical Devices 0.03%

Annual Asset Resilience Ratio for Glaukos Corp (2013–2024)

The table below shows the annual Asset Resilience Ratio data for Glaukos Corp.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 15.32% $149.29 Million $974.76 Million -6.16pp
2023-12-31 21.48% $201.96 Million $940.41 Million -0.23pp
2022-12-31 21.71% $233.17 Million $1.07 Billion -6.05pp
2021-12-31 27.76% $313.34 Million $1.13 Billion -2.85pp
2020-12-31 30.61% $307.77 Million $1.01 Billion +16.98pp
2019-12-31 13.63% $111.55 Million $818.40 Million -39.84pp
2018-12-31 53.47% $110.67 Million $206.97 Million -3.52pp
2017-12-31 56.99% $94.51 Million $165.84 Million -9.45pp
2016-12-31 66.43% $89.27 Million $134.37 Million +6.82pp
2015-12-31 59.62% $69.55 Million $116.66 Million +59.39pp
2014-12-31 0.23% $60.00K $26.02 Million +0.04pp
2013-12-31 0.19% $60.00K $30.88 Million --
pp = percentage points

About Glaukos Corp

NYSE:GKOS USA Medical Devices
Market Cap
$7.77 Billion
Market Cap Rank
#3116 Global
#1066 in USA
Share Price
$135.27
Change (1 day)
+1.39%
52-Week Range
$74.67 - $143.67
All Time High
$161.22
About

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. The company offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathw… Read more